Table 6.
Effects of serum on the antiviral activity of DBPR110 in HCV1b replicon cell lines
| Serum concn (%)b | DBPR110 potency |
|||
|---|---|---|---|---|
| EC50 (pM)a | Fold shift in EC50 | EC90 (pM)a | Fold shift in EC90 | |
| FBS | ||||
| 10 | 4.3 ± 0.8 | 1.0 | 9.3 ± 3.4 | 1.0 |
| 20 | 8.1 ± 1.6 | 1.9 | 23.8 ± 11.0 | 2.6 |
| 30 | 7.9 ± 0.9 | 1.8 | 21.6 ± 17.0 | 2.3 |
| 40 | 13.2 ± 1.7 | 3.1 | 35.1 ± 7.4 | 3.8 |
| 50 | 21.5 ± 10.0 | 5.0 | 41.9 ± 7.2 | 4.5 |
| NHS | ||||
| 10 | 33.5 ± 0.4 | 1.0 | 41.6 ± 1.3 | 1.0 |
| 40 | 210.9 ± 6.3 | 6.3 | 588.1 ± 45.9 | 14.1 |
a
Means ± standard deviations determined from the parental cell line (n = 3).
b
FBS, fetal bovine serum; NHS, normal human serum.